GlobalData on MSN3d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
pharmaceuticalcommerce3d
ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...
Hosted on MSN3d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
Monthly Prescribing Reference4d
FDA Allows Use of Recombinant BCG Through Expanded Access Program
Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...
FiercePharma4d
Amid Merck supply squeeze, ImmunityBio and Serum Institute snag FDA blessing for BCG expanded access program
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...
FDA authorizes ImmunityBio to provide rBCG to urologists amid shortages
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
FDA批准ImmunityBio膀胱癌药物扩大使用范围
加利福尼亚州卡尔弗城 - 市值24.6亿美元的免疫疗法公司ImmunityBio, Inc. (NASDAQ: IBRX )获得美国食品和药物管理局（FDA）授权，批准其扩大使用计划（EAP），为美国膀胱癌治疗提供新的卡介苗（BCG）来源。这一进展是为了应对过去一年影响患者治疗的TICE® BCG短缺问题。根据 InvestingPro ...
Business Wire4d
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE ® BCG Shortage
In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated they were unable to treat patients in the last 12 months due to a lack of access to TICE ® BCG. The alternative BCG source ...